Hello, everyone, and how was your weekend? Hopefully, the respite was relaxing. Now, though, that familiar routine of meetings and deadlines and whatever else has resumed in full force. We are no different, of course, and so we are fortifying our selves with that age-old cup of stimulation - Rain Forest Nut is our choice this morning - and invite you to join us. Meanwhile, please keep us in mind if you hear anything interesting. Hope your day goes well...
Lung Cancer Genomic Mapping Points Toward New Targets (New York Times)
Roche Ramps Up Alzheimer's Drug Trial (Reuters)
AstraZeneca Halts Development Of Obesity Drug (MarketWatch)
UK's NICE Reconsiders Glaxo Lupus Drug (Reuters)
Peregrine Stock Jumps On Lung Cancer Drug Study (Bloomberg News)
Roche Eyes NJ And NY For Research Center (Star-Ledger of New Jersey)
Abbott And Astellas Partner For CMV Vaccine (Pharma Times)
Use of Gilead Truvada HIV Pill May Be Limited In US (Reuters)
Mylan Promotes EpiPen Use In Schools (New York Times)
Ireland Drug Bill Could Drop Under New Bill (Irish Times)
Pharma Exec Arrested In Pakistani Ephredrine Scandal (The Nation)
EDITOR'S NOTE: Please check this post for updates during the day
sunrise pic thx to benimoto on flickr






8 Comments
ed
This was similarly done with Xalkori (crizotinib), which targets a rearranged gene in some adenocarcinoma lung cancer patients entered clinical trials for lung cancers with the rearrangement. The rearrangement was so rare, about 1,500 patients were tested to find 82 whose cancers had it. They were the ones included in the study.
Xalkori (crizotinib) was originally developed as a clinical therapy for patients who carried the CMET mutation. Serendipity led to the recognition that the responding subpopulation was actually carrying a heretofore-unrecognized ALK gene rearrangement (accidental success). Were it not for the clinical "observation" of response in patients, the investigators conducting this trial would have been unlikely to make the discoveries that today provide such good clinical responses in others. As Dr. Robert Nagourney of Rational Therapeutics puts it, "these patients and their disease entities educated the molecular biologists."
Who is kidding whom here?
Yet, more often than not, it is exactly the same therapy that they would have received from their home-town oncologists, who read the same journals, attended the same meetings and adhered to the same NCCN or ASCO guidelines as the "best and brightest" academics. Then they conveniently chalk these patient's failures up to the biology of the disease and the patient's drug resistance rather than examining the more discomforting reality that "protocol therapy" doesn't work for famous patients any better than it does for anyone else.
Hitchens might have improved his chances for survival if he had not smoked or drank alcohol. Likewise epidermoid (squamous cell)carcinoma of the lung us almost 100% caused by cigarette smoking. Lets stop spending money on these really low percentage approaches and get back to basics. Don't smoke cigarettes and it's virtually impossible you will get squamous cell carcinoma of the lung, especially now that generating second hand smoke will get you an audience with the Lord High Executioner, Mayor Bloomberg.